Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
R-Pharm
OncoResponse, Inc.
Massachusetts General Hospital
Maastricht University Medical Center
Genzada Pharmaceuticals USA, Inc.
Beijing Immunochina Medical Science & Technology Co., Ltd.
CureVac
Threshold Pharmaceuticals
National Cancer Institute (NCI)